Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion

  • M. Smollich, M. Götte, C. Kersting, J. Fischgräbe, L. Kiesel, P. Wülfing
  • Breast Cancer Research and Treatment, April 2007, Springer Science + Business Media
  • DOI: 10.1007/s10549-007-9589-5

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Professor Martin Götte